Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE)-- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman ...
Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a ...
Recursion Pharmaceuticals’s stock price closed at $3.53. It is down -23.76% in the last 3 months and down -57.67% in the last 12 months. Recursion Pharmaceuticals saw 3 positive EPS revisions and 1 ...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Major investors Nvidia and Novo Holdings A/S have fully ...
Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock tumbled 12% Wednesday morning after regulatory filings revealed that NVIDIA (NASDAQ:NVDA) had completely divested its stake in the ...
A decision tree regression system incorporates a set of if-then rules to predict a single numeric value. Decision tree regression is rarely used by itself because it overfits the training data, and so ...
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.90, marking a -4.88% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.51% for ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results